Go Pro

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare logo
$436.22 -1.90 (-0.43%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
8
Buy
15

Based on 24 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 8 have given a hold rating, and 15 have given a buy rating for HCA.

Consensus Price Target

$463.70
6.30% Upside
According to the 24 analysts' twelve-month price targets for HCA Healthcare, the average price target is $463.70. The highest price target for HCA is $579.00, while the lowest price target for HCA is $380.00. The average price target represents a forecasted upside of 6.30% from the current price of $436.23.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HCA Analyst Ratings Over Time

TypeCurrent Forecast
9/23/25 to 9/23/26
1 Month Ago
8/24/25 to 8/24/26
3 Months Ago
6/25/25 to 6/25/26
1 Year Ago
9/23/24 to 9/23/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
15 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
7 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$463.70$462.64$503.00$407.75
Forecasted Upside6.30% Upside7.79% Upside29.93% Upside-0.34% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HCA Healthcare Stock vs. The Competition

TypeHCA HealthcareHealthcare CompaniesBroader Market
Consensus Rating Score
2.58
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside5.83% Upside708.25% Upside17.93% Upside
News Sentiment Rating
Neutral News

See Recent HCA News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/22/2026
Sean Dodge
Not Rated
Initiated CoverageMarket PerformOutperform$495.00+12.98%
9/18/2026
Leerink Partners logo
Leerink Partners
2 of 5 stars
Whit Mayo
Whit Mayo
2 of 5 stars
Reiterated RatingOutperform$492.00+14.29%
9/8/2026
Ben Hendrix
Ben Hendrix
3 of 5 stars
Reiterated RatingOutperform$435.00+7.39%
9/4/2026 Reiterated RatingHold (C+)
8/20/2026Lower TargetNeutral$490.00 ➝ $425.00+4.83%
8/3/2026Boost TargetEqual Weight$369.00 ➝ $381.00-7.87%
7/28/2026Lower TargetBuy$558.00 ➝ $485.00+24.44%
7/28/2026Lower TargetOutperform$525.00 ➝ $475.00+21.88%
7/27/2026Lower TargetBuy$635.00 ➝ $579.00+49.09%
7/27/2026 Set Target$476.00+22.57%
7/27/2026Lower TargetUnderweight$425.00 ➝ $380.00-2.15%
7/27/2026Lower TargetBuy$535.00 ➝ $495.00+27.98%
7/27/2026Lower TargetOutperform$520.00 ➝ $485.00+26.30%
7/27/2026Lower TargetOverweight$475.00 ➝ $435.00+13.79%
7/27/2026Lower TargetEqual Weight$402.00 ➝ $387.00+1.23%
7/27/2026Lower TargetNeutral$396.00 ➝ $393.00+2.80%
7/15/2026Reiterated RatingMarket Perform
7/14/2026 Set Target$450.00+23.47%
7/7/2026Set Target$528.00+23.26%
7/7/2026Lower TargetOverweight$588.00 ➝ $525.00+25.90%
6/22/2026Lower TargetBuy$500.00 ➝ $431.00+14.99%
5/4/2026 Lower TargetBuy$560.00 ➝ $500.00+15.88%
4/27/2026Lower TargetOverweight$560.00 ➝ $530.00+19.56%
11/27/2025 DowngradeStrong-BuyHold
10/27/2025Boost TargetNeutral$430.00 ➝ $470.00+1.71%
7/28/2025DowngradeOutperformPeer Perform
4/9/2025Initiated CoverageNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:02 PM ET.


Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 22, 2026. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

  • The company recently completed the acquisition of The College of Health Care Professions, an institution serving over 8,000 students annually through 10 Texas campuses and online programs. This strategic move allows HCA Healthcare, Inc. to directly address staffing shortages by creating a dedicated pipeline for trained healthcare professionals, which is a critical operational challenge for hospital systems.
  • HCA Healthcare, Inc. is executing a significant strategic shift to become a broader healthcare company rather than just a hospital system, with the CFO stating a goal to reach 20 outpatient facilities per hospital by 2030. This expansion into ambulatory surgery centers, urgent care, and other outpatient locations diversifies revenue streams and aligns with the industry trend of shifting care from expensive inpatient settings to more cost-effective outpatient environments.
  • The stock currently trades at $438.14, which is below the consensus price target of $462.27 set by 23 ratings firms. This valuation gap suggests potential upside for investors, supported by a "Moderate Buy" consensus rating and a P/E ratio of 14.67, which is relatively low for a healthcare provider with consistent revenue growth.
  • HCA Healthcare, Inc. recently reported strong financial performance, with Q2 2026 revenue of $20.23 billion beating analyst estimates of $19.76 billion and EPS of $7.59 exceeding the consensus of $7.56. The company also maintains a stable dividend yield of 0.73% with a low payout ratio of 10.45%, indicating that it has ample cash flow to sustain shareholder returns while investing in growth.
  • Institutional investors are showing renewed confidence in the stock, with several major funds increasing their holdings in the second quarter of 2026. For example, Wellington Management Group LLP increased its stake by 20.5% and Andra AP fonden grew its holdings by 21.1%, suggesting that professional money managers are positioning for long-term growth in the healthcare sector.

HCA Healthcare
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

  • The company is facing significant headwinds from patient affordability issues, with the CFO noting that patients are owing more but paying less amid economic strain. This has led to a slowdown in elective surgery volumes as insurance coverage erodes, which directly impacts revenue from high-margin procedures and increases the risk of bad debt.
  • HCA Healthcare, Inc. is involved in legal disputes with insurance providers, including a lawsuit filed by HCA-affiliated hospitals in Texas against Independence Blue Cross over claim denials. These conflicts over prior authorization and denied claims create uncertainty in revenue cycle management and may lead to prolonged delays in cash collection, affecting liquidity.
  • Short interest in the stock has been rising, with shares shorted increasing to 6,135,558 as of August 31, 2026, representing a 0.14% month-over-month increase. This growing short position indicates that some investors are betting against the stock, potentially due to concerns about the company's ability to navigate the current economic and regulatory environment.
  • The company has seen a decline in its consensus price target from $537.73 in March 2026 to $462.27 in September 2026, reflecting a more cautious outlook from analysts. This downward revision suggests that the market is pricing in higher risks related to patient volume, reimbursement rates, and operational challenges.
  • HCA Healthcare, Inc. is lagging behind insurance payers in the adoption of AI for claims processing, with the CFO acknowledging that the company is "behind the payers" in this area. This technological gap could result in inefficiencies in revenue cycle management and increased administrative costs, putting pressure on margins in a competitive healthcare landscape.

HCA Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $463.70, with a high forecast of $579.00 and a low forecast of $380.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted upside of 6.30% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 1 downgrade by analysts.

Analysts like HCA Healthcare more than other "healthcare" companies. The consensus rating for HCA Healthcare is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how HCA compares to other companies.


MarketBeat monitors more than a dozen sources for HCA Healthcare analyst ratings, with the most recent rating issued on 9/22/2026.
From Our Partners